ATE418344T1 - Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten - Google Patents

Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten

Info

Publication number
ATE418344T1
ATE418344T1 AT01987655T AT01987655T ATE418344T1 AT E418344 T1 ATE418344 T1 AT E418344T1 AT 01987655 T AT01987655 T AT 01987655T AT 01987655 T AT01987655 T AT 01987655T AT E418344 T1 ATE418344 T1 AT E418344T1
Authority
AT
Austria
Prior art keywords
treating diseases
fusion cells
fusion
cytokine compositions
cytokine
Prior art date
Application number
AT01987655T
Other languages
English (en)
Inventor
Tsuneya Ohno
Original Assignee
Tsuneya Ohno
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsuneya Ohno filed Critical Tsuneya Ohno
Application granted granted Critical
Publication of ATE418344T1 publication Critical patent/ATE418344T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01987655T 2000-10-20 2001-10-22 Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten ATE418344T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24215400P 2000-10-20 2000-10-20

Publications (1)

Publication Number Publication Date
ATE418344T1 true ATE418344T1 (de) 2009-01-15

Family

ID=22913659

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01987655T ATE418344T1 (de) 2000-10-20 2001-10-22 Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten

Country Status (9)

Country Link
US (2) US20020168351A1 (de)
EP (1) EP1368061B1 (de)
JP (1) JP2004511503A (de)
AT (1) ATE418344T1 (de)
AU (2) AU2599002A (de)
CA (1) CA2426366A1 (de)
DE (1) DE60137146D1 (de)
IL (1) IL155514A0 (de)
WO (1) WO2002032378A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273753B2 (en) * 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
DE10112851C1 (de) * 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
CN1168740C (zh) * 2001-04-04 2004-09-29 上海美恩生物技术有限公司 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途
WO2003101586A1 (en) * 2002-05-31 2003-12-11 Apollo Life Sciences Pty Limited Cell recovery
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
US20040115224A1 (en) * 2002-12-16 2004-06-17 Tsuneya Ohno Preparation and administration of hybrid cell vaccines for the prevention of cancer
US20050180951A1 (en) * 2004-02-12 2005-08-18 Tsuneya Ohno Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
JPWO2005083062A1 (ja) * 2004-02-26 2008-01-17 ジェノミディア株式会社 細胞ワクチン
WO2005084387A2 (en) * 2004-03-02 2005-09-15 Tsuneya Ohno Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer
US7225078B2 (en) * 2004-11-03 2007-05-29 Halliburton Energy Services, Inc. Method and system for predicting production of a well
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
EP3757130A1 (de) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Verfahren zur behandlung von blutkrebs
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
AU2015210750B2 (en) 2014-01-31 2020-08-20 Children's Medical Center Corporation Antibody molecules to TIM-3 and uses thereof
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049803A (en) * 1976-04-26 1977-09-20 Bristol-Myers Company Augmentation of blood levels of aspirin
US20010012632A1 (en) * 1995-03-31 2001-08-09 Muriel Moser Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response
DE19633731A1 (de) * 1996-08-21 1998-02-26 Johann Hinrich Prof Dr Peters Hybridzellen zur Steigerung der Immunogenität von Tumorzellen
DE69839215T2 (de) * 1997-04-15 2009-03-19 Dana-Farber Cancer Institute, Inc., Boston Dendritische zellhybride
US6406699B1 (en) * 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
WO2001062902A1 (en) * 2000-02-27 2001-08-30 Eberhard-Karls-Universität Tübingen Universitätsklinikum Hybrid cell vaccines
US20040115224A1 (en) * 2002-12-16 2004-06-17 Tsuneya Ohno Preparation and administration of hybrid cell vaccines for the prevention of cancer
US20050180951A1 (en) * 2004-02-12 2005-08-18 Tsuneya Ohno Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
WO2005084387A2 (en) * 2004-03-02 2005-09-15 Tsuneya Ohno Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer

Also Published As

Publication number Publication date
EP1368061A2 (de) 2003-12-10
WO2002032378A3 (en) 2003-02-27
CA2426366A1 (en) 2002-04-25
EP1368061B1 (de) 2008-12-24
US20040028663A1 (en) 2004-02-12
AU2002225990B2 (en) 2007-07-19
US20020168351A1 (en) 2002-11-14
WO2002032378A2 (en) 2002-04-25
IL155514A0 (en) 2003-11-23
DE60137146D1 (de) 2009-02-05
JP2004511503A (ja) 2004-04-15
EP1368061A4 (de) 2005-10-19
WO2002032378A9 (en) 2003-06-26
AU2599002A (en) 2002-04-29

Similar Documents

Publication Publication Date Title
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
ATE276758T1 (de) Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
HRP20020787B1 (hr) Postupak liječenja upotrebom kompleksa ligand-imunogen
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
CY1120977T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
DE69929232D1 (de) Virusähnliche partikel zur induktion von autoantikörpern
ATE494899T1 (de) Zusammensetzung bestehend aus phy906 und chemotherapeutika
IL138424A0 (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
DE69433013D1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
ATE497770T1 (de) Pharmazeutische formulierungen von decitabin
DE60033649D1 (de) Verbindungen und therapeutische methoden
MY209484A (en) Cpg amphiphiles and uses thereof
TR200001948T2 (tr) Mikobakteri vaccaesinden türetilen kompozisyonlar ve bunların kullanımları için metotlar.
BR0015597A (pt) Uso de anticorpos como vacinas
EP1037918A4 (de) Verfahren und zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
MXPA03010261A (es) Metodos para tratar cancer.
MY127452A (en) Vaccines.
MA27474A1 (fr) Vaccin
DE69706657D1 (de) Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen
MEP39708A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
FR2809725B1 (fr) Propanolaminotetralines, leur preparation et compositions pharmaceutiques en contenant
DE60044198D1 (de) Aktivierung antigen-spezifischer t-zellen mit virus/antigen-behandelten dendritischen zellen
UA39044A (uk) Склад для лікування хвороб пародонта

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties